DENTSPLY SIRONA (NASDAQ:XRAY) had its price objective boosted by equities researchers at UBS Group from $42.00 to $53.00 in a research report issued to clients and investors on Tuesday, www.analystratings.com reports. The firm presently has a “neutral” rating on the medical instruments supplier’s stock. UBS Group’s price objective would suggest a potential upside of 6.94% from the stock’s previous close.

XRAY has been the subject of a number of other reports. BidaskClub upgraded shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a research report on Wednesday, November 21st. Zacks Investment Research reiterated a “hold” rating on shares of DENTSPLY SIRONA in a research report on Saturday, November 17th. Barclays reiterated a “hold” rating and set a $39.00 price objective on shares of DENTSPLY SIRONA in a research report on Sunday, January 6th. Robert W. Baird upped their price objective on shares of DENTSPLY SIRONA from $42.00 to $50.00 and gave the stock a “neutral” rating in a research report on Monday, March 4th. Finally, HC Wainwright reiterated a “neutral” rating and set a $49.00 price objective (up from $40.00) on shares of DENTSPLY SIRONA in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company. DENTSPLY SIRONA has an average rating of “Hold” and a consensus target price of $51.33.

XRAY stock opened at $49.56 on Tuesday. The company has a market cap of $10.97 billion, a P/E ratio of 24.66, a P/E/G ratio of 2.33 and a beta of 1.06. DENTSPLY SIRONA has a 1 year low of $33.93 and a 1 year high of $58.26. The company has a quick ratio of 1.14, a current ratio of 1.76 and a debt-to-equity ratio of 0.31.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Friday, March 1st. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.04. The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DENTSPLY SIRONA had a negative net margin of 41.97% and a positive return on equity of 8.68%. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.82 EPS. As a group, research analysts expect that DENTSPLY SIRONA will post 2.31 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Norges Bank acquired a new position in DENTSPLY SIRONA in the 4th quarter valued at approximately $73,734,000. FMR LLC increased its position in DENTSPLY SIRONA by 19.0% in the 4th quarter. FMR LLC now owns 1,218,174 shares of the medical instruments supplier’s stock valued at $45,329,000 after acquiring an additional 194,701 shares during the period. Kentucky Retirement Systems acquired a new position in DENTSPLY SIRONA in the 4th quarter valued at approximately $360,000. Headinvest LLC increased its position in DENTSPLY SIRONA by 84.8% in the 4th quarter. Headinvest LLC now owns 157,682 shares of the medical instruments supplier’s stock valued at $5,867,000 after acquiring an additional 72,356 shares during the period. Finally, Abacus Planning Group Inc. acquired a new position in DENTSPLY SIRONA in the 4th quarter valued at approximately $227,000. Hedge funds and other institutional investors own 96.30% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Read More: Debt-To-Equity Ratio

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.